IP Library › Granted Patent US 11,364,198
Granted Patent B2
US 11,364,198 · App. 16/377,126 · Granted Jun 21, 2022

Polymeric emulsion delivery systems

Inventors: Arturo Angel (Santa Rosa, CA); Chandelle Hermes (Petaluma, CA)
Assignee: BAUSCH HEALTH IRELAND LIMITED
A61K9/107A61K9/0014A61K9/06A61K31/203A61K31/4436A61K31/573A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,364,198
App. No.
16/377,126
Granted
Jun 21, 2022
Kind
B2
Abstract

Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.

Claims (24)

1. A topical composition comprising:

a liquid oil component;

a cross-linked homopolymer based on acrylic acid as a first emulsifier; and

water;

wherein the composition does not comprise a cross-linked copolymer of acrylic acid and acrylic acid esters; and

wherein the composition forms a stable oil-in-water emulsion.

2. The topical composition of claim 1 , wherein the liquid oil component is present in an amount of about 30% or less by weight of the composition.

3. The topical composition of claim 2 , wherein the liquid oil component is present in an amount of about 20% or less by weight of the composition.

4. The topical composition of claim 1 , wherein the first emulsifer is present in an amount of about 0.01-5% by weight of the composition.

5. The topical composition of claim 4 , wherein the first emulsifier is present in an amount of about 0.01-3% by weight of the composition.

6. The topical composition of claim 1 , wherein the ratio of the amount of the liquid oil component to that of the first emulsifer is in the range of about 1:1 to about 28:1.

7. The topical composition of claim 6 , wherein the ratio of the amount of the liquid oil component to that of the first emulsifer is in the range of about 1:1 to about 20:1.

8. The topical composition of claim 6 , wherein the ratio of the amount of the liquid oil component to that of the first emulsifier is in the range of about 3:1 to about 10:1.

9. The topical composition of claim 1 , wherein first emulsifer is a carbomer homopolymer type A and/or a carbomer homopolymer type C.

10. The topical composition of claim 1 , wherein the liquid oil component comprises mineral oil, light mineral oil, a fatty alcohol, a monocarboxylic acid ester, a dicarboxylic acid ester, a medium chain triglyceride, a long chain triglyceride, or a combination thereof.

11. The topical composition of claim 1 , wherein the composition further comprises a nonionic, anionic, or cationic surfactant in an amount up to about 0.5% by weight of the composition.

12. The topical composition of claim 1 , further comprising an active agent.

13. A topical composition, wherein the composition comprises an oil-in-water emulsion, wherein the emulsion comprises:

a liquid oil component, wherein the liquid oil component is in an amount of about 30% or less by weight of the composition;

a cross-linked homopolymer based on acrylic acid in an amount of about 0.01-5% by weight of the composition; and

water;

wherein the composition does not comprise a cross-linked copolymer of acrylic acid and acrylic acid esters.

14. The topical composition of claim 13 , wherein the polymer is a cross-linked homopolymer based on acrylic acid.

15. The topical composition of claim 13 , further comprising an active agent.

Assignments (15)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT FOR THE NOTEHOLDER SECURED PARTIES
Reel/Frame 051797/0491 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 051797/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2019
From: ANGEL, ARTURO; HERMES, CHANDELLE
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 051395/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2019
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 051458/0050 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
Continuity (2)
Provisional Application 62653369 · Apr 5, 2018
Related Publication 20190307682A1 · Oct 10, 2019